December 24, 2014 8:11 PM ET


Company Overview of Kymab Limited

Company Overview

Kymab Limited, a biopharmaceutical company, engages in the discovery and development of human monoclonal antibody therapeutics. The company is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. The company focuses on using the Kymouse platform for the discovery, development, and commercialization of antibody based medicines. Kymab Limited was founded in 2009 and is based in Cambridge, United Kingdom.

Meditrina (B260)

Babraham Research Campus

Cambridge,  CB22 3AT

United Kingdom

Founded in 2009


44 1223 833301


44 1223 839133

Key Executives for Kymab Limited

Chairman and Chief Executive Officer
Chief Business Officer
Senior Vice President of Technology Development
Consultant Finance Director
Compensation as of Fiscal Year 2014.

Kymab Limited Key Developments

Kymab Defends Patent Action in UK

Kymab announced that it has notified the English Court that it will defend the UK patent proceedings brought by Regeneron in respect of European patent EP1360287. Regeneron initiated these proceedings in September 2013. Kymab will defend the UK patent action on the grounds of non-infringement and invalidity of the patent. Earlier, in June 2013, Kymab opposed the equivalent Regeneron European patent in the European Patent Office. The opposition proceedings are pending.

Kymab Announces Kymouse Antibody Discovery Agreement with Novo Nordisk

Kymab announced an agreement in therapeutic antibody discovery. Novo Nordisk has been granted a non-exclusive licence to Kymab's proprietary Kymouse(TM) human antibody discovery platform to discover, develop and commercialise therapeutic monoclonal antibody drugs for human diseases. The licence provides Novo Nordisk with access to the Kymouse HK and Kymouse HL transgenic human antibody mouse strains, which can generate highly selective, potent, human antibody drug candidates. The Kymouse HL strain produces antibodies with human heavy and lambda light chains whereas Kymouse HK generates antibodies with human heavy and kappa light chains. By using these strains in combination, a diverse pool of human antibodies can be created with both classes of light chains fully represented.

Kymab Limited Presents at BioCapital Europe 2013, Apr-17-2013 11:40 AM

Kymab Limited Presents at BioCapital Europe 2013, Apr-17-2013 11:40 AM. Venue: Sofitel Amsterdam The Grand, Oudezijds Voorburgwal 197, 1012 EX Amsterdam, Netherlands.

Similar Private Companies By Industry

Company Name Region
Perfectus Biomed Limited Europe
Ubiquigent Ltd. Europe
Locate Therapeutics Limited Europe
Xcellsyz Ltd. Europe
Ruskinn Life Sciences Ltd. Europe

Recent Private Companies Transactions

Private Placement
May 16, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kymab Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at